C. difficile

Studies point to the life-saving record of fecal transplants for patients infected with C. diff, despite a recent death. Doctors are now testing the procedure for other conditions.

A review finds that for several conditions, poop from certain healthy people is more likely to provide relief for recipients.

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

Researchers build a mathematical model that can predict whether a mouse will be infected by Clostridium difficile based on the microbes found in its GI tract.

In a preliminary study, patients with recurring Clostridium difficile infections found relief from diarrhea by ingesting frozen fecal matter from healthy volunteers.

A study shows that fecal transplants in an oral capsule form are an effective treatment for Clostridium difficile infection.

Mice fed a mix of six strains of bacteria were able to fight a C. difficile infection that causes deadly diarrhea and is resistant to most types of treatment.

Clostridium difficile is evolving more robust toxicity, repeatedly attacking its victims, and driving the search for alternative therapies to fight the infection.